Cargando…

Scale-up of the DMPA-SC in Nigeria: Why policy matters

BACKGROUND: Injectable contraceptives have contributed substantially to Nigeria's rise in modern family planning methods usage. They are one of the most commonly used and preferred means of contraception among women in the country. Enabling policies are required to assure contraceptive access,...

Descripción completa

Detalles Bibliográficos
Autores principales: Akinyemi, Oluwaseun, Danfakha, Nicole, Adefalu, Adewole, Easley, Ebony, Afolabi, Kayode, Latunji, Olajimi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768394/
https://www.ncbi.nlm.nih.gov/pubmed/36544189
http://dx.doi.org/10.1186/s12905-022-02109-x
_version_ 1784854157112377344
author Akinyemi, Oluwaseun
Danfakha, Nicole
Adefalu, Adewole
Easley, Ebony
Afolabi, Kayode
Latunji, Olajimi
author_facet Akinyemi, Oluwaseun
Danfakha, Nicole
Adefalu, Adewole
Easley, Ebony
Afolabi, Kayode
Latunji, Olajimi
author_sort Akinyemi, Oluwaseun
collection PubMed
description BACKGROUND: Injectable contraceptives have contributed substantially to Nigeria's rise in modern family planning methods usage. They are one of the most commonly used and preferred means of contraception among women in the country. Enabling policies are required to assure contraceptive access, security, and use. This study aimed to investigate the policy environment and how it supports or limits Nigeria's introduction and scale-up of subcutaneous depot-medroxyprogesterone acetate (DMPA-SC). METHODS: The design of this mixed-methods study was cross-sectional. Desk reviews of policy papers, key informant interviews, and in-depth interviews were used to obtain information from respondents about the introduction of DMPA-SC in Nigeria and how existing policies influenced its scale-up. Data on DMPA-SC and other injectables were gathered from Nigeria's national electronic logistics management information system. RESULTS: The findings suggest that policies such as task-shifting and task-sharing, cost-free policies, reproductive health policies, and others created an enabling environment for the scale-up of DMPA-SC adoption in Nigeria. The inclusion of DMPA-SC on the essential medicines list and the approved patent medicines list facilitated the scale-up process by ensuring private sector participation, removing economic barriers to access, fostering greater collaboration among health worker cadres, improving intersectoral partnerships, and improving logistics and client access. Despite significant anomalies in some implementing policies, injectable contraceptive consumption data demonstrate a progressive increase in DMPA-SC use during the study period. The results also indicate that policy initiatives have a favorable impact on the use of DMPA-SC throughout the country. CONCLUSION: The existence of policies, the active participation of stakeholders, and the political will of the Nigerian health system's leadership have all aided in the scaling-up of the DMPA-SC. Understanding how to build an enabling policy climate is critical for providing women with family planning options. These lessons from Nigeria emphasize the importance of these levers, which should be considered by teams intending to introduce innovative health products, particularly in developing countries. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12905-022-02109-x.
format Online
Article
Text
id pubmed-9768394
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97683942022-12-21 Scale-up of the DMPA-SC in Nigeria: Why policy matters Akinyemi, Oluwaseun Danfakha, Nicole Adefalu, Adewole Easley, Ebony Afolabi, Kayode Latunji, Olajimi BMC Womens Health Research Article BACKGROUND: Injectable contraceptives have contributed substantially to Nigeria's rise in modern family planning methods usage. They are one of the most commonly used and preferred means of contraception among women in the country. Enabling policies are required to assure contraceptive access, security, and use. This study aimed to investigate the policy environment and how it supports or limits Nigeria's introduction and scale-up of subcutaneous depot-medroxyprogesterone acetate (DMPA-SC). METHODS: The design of this mixed-methods study was cross-sectional. Desk reviews of policy papers, key informant interviews, and in-depth interviews were used to obtain information from respondents about the introduction of DMPA-SC in Nigeria and how existing policies influenced its scale-up. Data on DMPA-SC and other injectables were gathered from Nigeria's national electronic logistics management information system. RESULTS: The findings suggest that policies such as task-shifting and task-sharing, cost-free policies, reproductive health policies, and others created an enabling environment for the scale-up of DMPA-SC adoption in Nigeria. The inclusion of DMPA-SC on the essential medicines list and the approved patent medicines list facilitated the scale-up process by ensuring private sector participation, removing economic barriers to access, fostering greater collaboration among health worker cadres, improving intersectoral partnerships, and improving logistics and client access. Despite significant anomalies in some implementing policies, injectable contraceptive consumption data demonstrate a progressive increase in DMPA-SC use during the study period. The results also indicate that policy initiatives have a favorable impact on the use of DMPA-SC throughout the country. CONCLUSION: The existence of policies, the active participation of stakeholders, and the political will of the Nigerian health system's leadership have all aided in the scaling-up of the DMPA-SC. Understanding how to build an enabling policy climate is critical for providing women with family planning options. These lessons from Nigeria emphasize the importance of these levers, which should be considered by teams intending to introduce innovative health products, particularly in developing countries. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12905-022-02109-x. BioMed Central 2022-12-21 /pmc/articles/PMC9768394/ /pubmed/36544189 http://dx.doi.org/10.1186/s12905-022-02109-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Akinyemi, Oluwaseun
Danfakha, Nicole
Adefalu, Adewole
Easley, Ebony
Afolabi, Kayode
Latunji, Olajimi
Scale-up of the DMPA-SC in Nigeria: Why policy matters
title Scale-up of the DMPA-SC in Nigeria: Why policy matters
title_full Scale-up of the DMPA-SC in Nigeria: Why policy matters
title_fullStr Scale-up of the DMPA-SC in Nigeria: Why policy matters
title_full_unstemmed Scale-up of the DMPA-SC in Nigeria: Why policy matters
title_short Scale-up of the DMPA-SC in Nigeria: Why policy matters
title_sort scale-up of the dmpa-sc in nigeria: why policy matters
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768394/
https://www.ncbi.nlm.nih.gov/pubmed/36544189
http://dx.doi.org/10.1186/s12905-022-02109-x
work_keys_str_mv AT akinyemioluwaseun scaleupofthedmpascinnigeriawhypolicymatters
AT danfakhanicole scaleupofthedmpascinnigeriawhypolicymatters
AT adefaluadewole scaleupofthedmpascinnigeriawhypolicymatters
AT easleyebony scaleupofthedmpascinnigeriawhypolicymatters
AT afolabikayode scaleupofthedmpascinnigeriawhypolicymatters
AT latunjiolajimi scaleupofthedmpascinnigeriawhypolicymatters